Plain-English translation of NCT07115446 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two new medications: , which is designed to attack cancer cells, and , which targets the androgen receptor that fuels prostate cancer growth. Researchers want to understand how safe this medication combination is, how well your body tolerates it, and how your body processes it.
Men with advanced prostate cancer often develop resistance to standard hormone treatments, leaving them with limited options. This trial explores whether combining two drugs that work in different ways might offer a new hope for patients whose cancer has progressed despite existing therapies.
You likely qualify if…
You likely don't qualify if…
You would receive both medications as part of this combination treatment at a research center. The study will monitor your safety and how your body responds through regular visits, blood tests, and scans. Participation involves a treatment phase where you receive the medication and a follow-up period where researchers track your progress and any side effects to understand whether this combination is safe and effective.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China